pneumococcal polysaccharide vaccine, polyvalent (PneumoVax 23, Pnu-Immune 23, PPSV-23)

From Aaushi
Jump to navigation Jump to search

Indications

* antibody levels remain at levels considered protective beyond 5 years in patients with autoimmune rheumatic disease[18]

Contraindications

Caution:

pregnancy-category C

safety in lactation ?

Benefit/risk

Dosage

Injection:

Pharmacokinetics

Adverse effects

Drug interactions

* patients with lupus erythematosus or rheumatoid arthritis treated with immunosuppressive agents respond variably to the pneumococcal vaccine[5]

Mechanism of action

Notes

introduced in 1983

More general terms

Additional terms

References

  1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  3. 3.0 3.1 3.2 Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 16, 18. American College of Physicians, Philadelphia 1998, 2006, 2012, 2018.
  4. 4.0 4.1 Prescriber's Letter 9(1):5 2002
  5. 5.0 5.1 Journal Watch 22(4):30, 2002 Elkayam O et al Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Infect Dis 34:147, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11740700
  6. 6.0 6.1 Journal Watch 25(9):70, 2005 Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Barker L, Gay K, Jackson D, Orenstein WA, Arnold K, Schuchat A, Farley MM; Georgia Emerging Infections Program. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment. Lancet. 2005 Mar 2;365(9462):855-63. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15752529
  7. 7.0 7.1 Centers for Disease Control and Prevention (CDC) Recommended adult immunization schedule, United States 2002-2003 MMWR Morb Mortal Wkly Rep 2002; 51:904 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12418546
  8. 8.0 8.1 Fisman DN et al, Prior pneumococcal vaccination is associated with reduced death complications and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006; 42:1093 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16575726
  9. 9.0 9.1 Musher DM et al, Effect of pneumococcal vaccination: A comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infest Dis 2006, 43:1004 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16983612
  10. Prescriber's Letter 14(5): 2007 Revaccination With Pneumococcal Vaccine: Who Needs It? Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=230508&pb=PRL (subscription needed) http://www.prescribersletter.com
  11. 11.0 11.1 Huss A et al Efficacy of pneumococcal vaccination in adults: A meta-analysis. CMAJ 2009 Jan 6; 180:48. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19124790
    Andrews R and Moberley SA. The controversy over the efficacy of pneumococcal vaccine. CMAJ 2009 Jan 6; 180:18. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19124781
  12. 12.0 12.1 Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009. Ann Intern Med 2009 Jan 6; 150:40. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19124819
    Poland GA and Schaffner W. Immunization guidelines for adult patients: An annual update and a challenge. Ann Intern Med 2009 Jan 6; 150:53. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19124821
  13. Nuorti JP for the Centers for Disease Control and Prevention Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Morbidity and Mortality Weekly Report (MMWR) September 3, 2010 / 59(34);1102-1106 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm corresponding NGC guideline withdrawn Jan 2016
  14. Centers for Disease Control and Prevention (CDC) Recommended adult immunization schedule - United States 2012 MMWR Morb Mortal Wkly Rep 2012 / 61(04);1-7 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a9.htm
  15. 15.0 15.1 Kelly H1, Attia J, Andrews R, Heller RF. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine. 2004 Jun 2;22(17-18):2192-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15149776
  16. 16.0 16.1 Moore RA et al Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Family Practice 2000, 1:1-1 http://www.biomedcentral.com/1471-2296/1/1
  17. 17.0 17.1 Kobayashi M et al Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Weekly. September 4, 2015 / 64(34);944-947 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6434a4.htm
  18. 18.0 18.1 Broyde A et al. Longterm efficacy of an antipneumococcal polysaccharide vaccine among patients with autoimmune inflammatory rheumatic diseases. J Rheumatol 2016 Feb; 43:267. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26773117 <Internet> http://www.jrheum.org/content/43/2/267
  19. 19.0 19.1 19.2 19.3 19.4 19.5 Melville NA CDC Issues New Pneumococcal Vaccine Recommendations for Adults. Medscape. Feb 1, 2022
    Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:109-117 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35085226 Free article https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm
    Centers for Disease Control and Prevention. Pneumococcal vaccination: Information for healthcare professionals. CDC 2022 Jan 24 https://www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html